Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2017 Financial Results
October 31, 2017 07:30 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to...
Marinus Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference
September 21, 2017 16:01 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., Sept. 21, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
Marinus Pharmaceuticals Announces closing of Public Offering of Common Stock and full exercise of underwriter’s option to purchase additional shares
September 19, 2017 16:01 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (“Marinus” or the “Company”) announced the closing of an underwritten public offering of 10,733,334 shares...
Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
September 15, 2017 07:30 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., Sept. 15, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (“Marinus” or the “Company”) announced the pricing of an underwritten public offering of 9,333,334 shares...
Marinus Pharmaceuticals Announces Public Offering of Common Stock
September 14, 2017 16:01 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (“Marinus” or the “Company”) today announced that it intends to offer and sell shares of its common stock...
Marinus Announces Successful Clinical Trial Results and Declares CDKL5 Disorder Its Lead Pediatric Orphan Epilepsy Program for Ganaxolone
September 11, 2017 07:30 ET
|
Marinus Pharmaceuticals, Inc.
Substantial and Durable Anti-Seizure Efficacy Shown in Patients Suffering From Severe, Rare Genetic Epilepsy Marinus to Host Conference Call and Webcast Today at 9:00 am EDT RADNOR, Pa., Sept. ...
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2017 Financial Results
August 01, 2017 07:30 ET
|
Marinus Pharmaceuticals, Inc.
Data from Studies in Rare Pediatric Epilepsies and Severe Postpartum Depression Expected in 2nd Half On-track to Initiate Two Additional Phase 2 Trials Later This Year in Status Epilepticus and...
FDA Grants Orphan Drug Designation for Ganaxolone in CDKL5 Disorder
June 29, 2017 14:28 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., June 29, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
Marinus Pharmaceuticals Launches the Ganaxolone Clinical Program in Patients with Postpartum Depression
June 27, 2017 07:30 ET
|
Marinus Pharmaceuticals, Inc.
Program to Evaluate Intravenous and Oral Ganaxolone in Patients with Severe or Moderate Postpartum Depression RADNOR, Pa., June 27, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc....
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2017 Financial Results
May 01, 2017 07:30 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., May 01, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to...